To examine this possibility, survivin-specific T cells were treated with the cell culture supernatants from either the CCR9 siRNA knockdown (CCR9lo) or control (CCR9hi) MCF7 tumor cells overnight and then challenged against CCR9hi or CCR9lo MCF7 cells in the cytotoxicity assay. The gene discussed is CCR9; the disease is neoplasm.